Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 31 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing the receipt of final approvals from the USFDA for two medications: Venlafaxine Extended-Release Tablets and Pregabalin Extended-Release Tablets. The press release details the uses of these medications, including treatment for depression and nerve pain, and mentions their expected manufacturing location in Ahmedabad, India. Additionally, the release highlights the annual sales figures for both drugs in the United States, indicating their market potential.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 31-Aug-2022 titled Zydus receives two final approvals from the USFDA for Venlafaxine Extended-Release Tablets and Pregabalin Extended-Release Tablets

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases